---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073363"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:37:37.738758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed

## Summary
- Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17
- Non-GAAP Q4 net income $107M ($0.82 diluted EPS); Adjusted EBITDA $142M (+91% YoY)
- FY 2025: revenue $1,239M (+4%), SUBLOCADE $856M (+13%); GAAP net income $210M ($1.64 EPS); adj. EBITDA $428M (+20%)
- Board authorized new $400M share repurchase program (up to 18 months) for opportunistic deployment
- FY 2026 guidance: SUBLOCADE $905M-$945M, adj. EBITDA $535M-$575M, non-GAAP opex $430M-$450M

## SEC filing metadata
- accession: 0001193125-26-073363
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/0001193125-26-073363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312526073363/d713689d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073363
- JSON: https://secwatch.observer/filing/0001193125-26-073363.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.